Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1409849

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1409849

Therapeutic BCG Vaccines Global Market Report 2024

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Therapeutic BCG Vaccines Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on therapeutic bcg vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for therapeutic bcg vaccines? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The therapeutic bcg vaccines market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Therapy BCG; Immune BCG
  • 2) By Demographics: Pediatrics; Adults
  • 3) By End Use: Hospitals; Clinics; Other End Users
  • Companies Mentioned: Merck & Co Inc.; Sanofi Pasteur; Japan BCG Laboratory; China National Biotec Group; Serum Institute of India Pvt. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

The therapeutic BCG vaccine is designed to provide protection against tuberculosis (TB). Not included in the standard NHS vaccination schedule, this vaccine, also known as Bacillus Calmette-Guerin vaccine, is administered as a single dose throughout a person's lifetime.

There are two primary types of therapeutic BCG vaccines such as therapy BCG and immune BCG. Therapy BCG is an intravesical immunotherapy specifically targeting early-stage bladder cancer by bolstering the immune system to target and eliminate cancer cells. This vaccine can be administered to both pediatric and adult populations and finds applications in hospitals, clinics, and various other healthcare settings.

The therapeutic BCG vaccines market research report is one of a series of new reports from The Business Research Company that provides therapeutic BCG vaccines market statistics, including therapeutic BCG vaccines industry global market size, regional shares, competitors with a therapeutic BCG vaccines market share, detailed therapeutic BCG vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the therapeutic BCG vaccines industry. This therapeutic BCG vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The therapeutic bcg vaccines market size has grown strongly in recent years. It will grow from $53.99 billion in 2023 to $57.14 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be attributed to several factors, including government initiatives aimed at tuberculosis (TB) control, strategies involving immune system modulation, global immunization programs to combat TB, utilization of therapeutic BCG for bladder cancer treatment, increased investments in vaccine manufacturing, and the emergence of drug-resistant strains of tuberculosis, which heightened the urgency for improved solutions and treatments.

The therapeutic bcg vaccines market size is expected to see strong growth in the next few years. It will grow to $72.54 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. Anticipated growth in the forecast period can be linked to several factors, including the expansion of therapeutic BCG vaccines to address other medical indications, intensified research focused on immunotherapy, worldwide efforts aimed at combating emerging infectious diseases, supportive regulatory measures facilitating vaccine development, and a dedicated emphasis on tuberculosis elimination initiatives. Key trends expected in this period encompass advancements in vaccine technology, optimization of supply chains, industry consolidation through partnerships, heightened emphasis on patient education and awareness, exploration of alternative vaccine delivery methods, and the exploration of personalized medicine approaches in vaccination strategies.

The increasing global prevalence of tuberculosis (TB) is anticipated to propel the growth of the therapeutic BCG vaccine market in the foreseeable future. Tuberculosis is an infectious disease with potentially severe consequences, primarily affecting the lungs. The transmission of tuberculosis occurs through the inhalation of small droplets containing bacteria, often expelled into the air through coughing or sneezing. BCG vaccines are designed to stimulate the immune system to combat infection without causing active TB, providing consistent protection against severe forms of the disease, including adolescent TB meningitis. The therapeutic use of BCG vaccines has witnessed a surge due to the rising incidence of tuberculosis cases worldwide. In October 2022, the World Health Organization reported an estimated 10.6 million new TB cases in 2021, marking a 4.5% increase from the previous year, with 1.6 million deaths, including 187,000 among HIV-positive individuals. Consequently, the escalating global tuberculosis cases are a significant driver for the growth of the therapeutic BCG vaccine market.

The increasing prevalence of drug-resistant tuberculosis (DR-TB) cases is poised to drive the expansion of the therapeutic BCG vaccine market in the coming years. Drug-resistant TB occurs when Mycobacterium tuberculosis, the causative bacteria, develops resistance to standard medications used for treatment. While therapeutic Bacillus Calmette-Guerin (BCG) vaccines are primarily recognized for preventing specific forms of TB, their potential application in addressing drug-resistant tuberculosis has gained attention. For example, as of November 2023, the Centers for Disease Control and Prevention reported that 8.4% of TB cases in the United States in 2022 exhibited resistance to at least isoniazid, including 1.4% with multidrug resistance. Within the U.S.-born population, 5.7% had isoniazid-resistant TB, with 0.7% classified as multidrug-resistant TB. The increasing incidence of drug-resistant TB cases is thus a key factor driving the therapeutic BCG vaccine market.

Strategic partnerships have become a prominent trend in the therapeutic BCG vaccine market as major companies prioritize collaboration to bolster their market standing. Notably, in July 2021, Zendal, a Spain-based pharmaceutical company, forged a partnership with IAVI, a US-based not-for-profit organization, to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials. MTBVAC, the only live, attenuated Mycobacterium tuberculosis vaccine in development, aims to prevent tuberculosis in adults and adolescents who lack effective vaccination options. Additionally, it is positioned as a potentially more potent and durable vaccine than BCG for infants. This strategic collaboration aligns with the broader trend of rapid vaccine development, particularly evident in the context of the COVID-19 pandemic.

Major players in the therapeutic BCG vaccine market are directing their efforts towards vaccine innovation for diverse therapeutic applications, such as BCG immunotherapy, to broaden their customer base and address expanding patient needs. BCG immunotherapy involves utilizing the BCG vaccine for immunotherapeutic purposes, particularly in treating certain types of cancer, such as bladder cancer. In a noteworthy development in July 2023, The Serum Institute of India, a biotechnology and biopharmaceuticals company, received government approval to export its BCG vaccine to Canada for immunotherapeutic use in bladder cancer treatment. This live freeze-dried preparation, derived from an attenuated strain of Mycobacterium bovis (Bacillus Calmette-Guerin), is administered intravenously in 40 mg and 80 mg presentations. The targeted administration directly into the bladder aims to impact cancer cells effectively while minimizing effects on other parts of the body, exemplifying the industry's focus on therapeutic innovation and strategic collaborations.

In February 2022, Sanofi S.A., a France-based multinational pharmaceutical and healthcare corporation, acquired Amunix for an undisclosed sum. This strategic acquisition grants Sanofi access to Amunix's innovative Pro-XTEN, XPAT, and XPAC technologies, facilitating the delivery of conditionally activated biologics representing the next phase in biopharmaceutical innovation. These technological advancements are expected to bolster Sanofi's efforts in advancing and diversifying its portfolio of advanced therapies, particularly in the field of oncology. With approximately 20 compounds currently in the developmental pipeline, this acquisition aligns seamlessly with Sanofi's existing research and development initiatives. Amunix, headquartered in the United States, specializes in immuno-oncology and is dedicated to the discovery, design, and development of novel biologics, proteins, and peptide therapeutics.

Major companies operating in the therapeutic bcg vaccines market report are Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., PowderJect Pharmaceuticals, Microgen, Taj Pharma Ltd., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, China Biotechnology Co Ltd., GlaxoSmithKline plc, Pfizer Inc., Bharat Biotech International Ltd., Biological E. Limited, Shanghai Institute of Biological Products Co. Ltd., Immunitor, Vakzine Projekt Management GmbH, Cipla Limited, Instituto Butantan, Chiron Corporation .

Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2023. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the therapeutic bcg vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The therapeutic BCG vaccines market consists of sales of vectors, peptides, proteins, DNA, and dendritic cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r11387

Table of Contents

1. Executive Summary

2. Therapeutic BCG Vaccines Market Characteristics

3. Therapeutic BCG Vaccines Market Trends And Strategies

4. Therapeutic BCG Vaccines Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Therapeutic BCG Vaccines Market Size and Growth

  • 5.1. Global Therapeutic BCG Vaccines Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Therapeutic BCG Vaccines Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Therapeutic BCG Vaccines Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Therapeutic BCG Vaccines Market Segmentation

  • 6.1. Global Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Therapy BCG
  • Immune BCG
  • 6.2. Global Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatrics
  • Adults
  • 6.3. Global Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other End Users

7. Therapeutic BCG Vaccines Market Regional And Country Analysis

  • 7.1. Global Therapeutic BCG Vaccines Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Therapeutic BCG Vaccines Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Therapeutic BCG Vaccines Market

  • 8.1. Asia-Pacific Therapeutic BCG Vaccines Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Therapeutic BCG Vaccines Market

  • 9.1. China Therapeutic BCG Vaccines Market Overview
  • 9.2. China Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Therapeutic BCG Vaccines Market

  • 10.1. India Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Therapeutic BCG Vaccines Market

  • 11.1. Japan Therapeutic BCG Vaccines Market Overview
  • 11.2. Japan Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Therapeutic BCG Vaccines Market

  • 12.1. Australia Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Therapeutic BCG Vaccines Market

  • 13.1. Indonesia Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Therapeutic BCG Vaccines Market

  • 14.1. South Korea Therapeutic BCG Vaccines Market Overview
  • 14.2. South Korea Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Therapeutic BCG Vaccines Market

  • 15.1. Western Europe Therapeutic BCG Vaccines Market Overview
  • 15.2. Western Europe Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Therapeutic BCG Vaccines Market

  • 16.1. UK Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Therapeutic BCG Vaccines Market

  • 17.1. Germany Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Therapeutic BCG Vaccines Market

  • 18.1. France Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Therapeutic BCG Vaccines Market

  • 19.1. Italy Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Therapeutic BCG Vaccines Market

  • 20.1. Spain Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Therapeutic BCG Vaccines Market

  • 21.1. Eastern Europe Therapeutic BCG Vaccines Market Overview
  • 21.2. Eastern Europe Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Therapeutic BCG Vaccines Market

  • 22.1. Russia Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Therapeutic BCG Vaccines Market

  • 23.1. North America Therapeutic BCG Vaccines Market Overview
  • 23.2. North America Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Therapeutic BCG Vaccines Market

  • 24.1. USA Therapeutic BCG Vaccines Market Overview
  • 24.2. USA Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Therapeutic BCG Vaccines Market

  • 25.1. Canada Therapeutic BCG Vaccines Market Overview
  • 25.2. Canada Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Therapeutic BCG Vaccines Market

  • 26.1. South America Therapeutic BCG Vaccines Market Overview
  • 26.2. South America Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Therapeutic BCG Vaccines Market

  • 27.1. Brazil Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Therapeutic BCG Vaccines Market

  • 28.1. Middle East Therapeutic BCG Vaccines Market Overview
  • 28.2. Middle East Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Therapeutic BCG Vaccines Market

  • 29.1. Africa Therapeutic BCG Vaccines Market Overview
  • 29.2. Africa Therapeutic BCG Vaccines Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Therapeutic BCG Vaccines Market, Segmentation By Demographics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Therapeutic BCG Vaccines Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Therapeutic BCG Vaccines Market Competitive Landscape And Company Profiles

  • 30.1. Therapeutic BCG Vaccines Market Competitive Landscape
  • 30.2. Therapeutic BCG Vaccines Market Company Profiles
    • 30.2.1. Merck & Co Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Sanofi Pasteur
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Japan BCG Laboratory
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. China National Biotec Group
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Serum Institute of India Pvt. Ltd.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Therapeutic BCG Vaccines Market Competitive Benchmarking

32. Global Therapeutic BCG Vaccines Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Therapeutic BCG Vaccines Market

34. Therapeutic BCG Vaccines Market Future Outlook and Potential Analysis

  • 34.1 Therapeutic BCG Vaccines Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Therapeutic BCG Vaccines Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Therapeutic BCG Vaccines Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!